Insights

  • Date

  • Content Type

  • Reset

Blog

The new economics of innovative therapies: Navigating emerging payment models

11.11.21

By Alberto Rubio

For years, market access strategies for new therapies almost exclusively depended on data supporting efficacy and safety. ..

Read More

Blog

Accelerating commercialization of advanced therapies: it’s time to map a new route to market

26.10.21

By Christian Schneider

For decades, advanced therapies have shown potential to disrupt the $1 trillion global pharmaceuticals...

Read More

Blog

Biopharma’s Big Inflection Point: There’s never been a better time to innovate with next-generation medicine

11.10.21

By Christian Schneider

In all of the years I have been tracking and helping to drive biotech innovation, I can say...

Read More

Blog

How to create a smart integrated drug development plan including considerations for cell and gene therapies

29.06.21

By Dr. Diane Seimetz

An integrated drug development plan is a critical tool for the efficient and effective progression from the R&D...

Read More

Blog

Risk Management Plans for ATMPs

13.06.21

By Maria Schacker

ATMPs are a relatively novel class of medicinal products with anew and very unique set of potential risks...

Read More

Blog

Neutralizing Antibody Assay Development – a key consideration for immunogenicity packages

1.06.21

By Jennifer Sales

Neutralising Antibodies, or NAbs, are a subclass of Anti-Drug Antibodies that may be formed during an unwanted immunogenic...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more